News
FDA approves Alkermes’ Lybalvi for schizophrenia and bipolar I disorder
Alkermes’ oral atypical antipsychotic drug Lybalvi has received approval from the US Food and Drug Administration for the treatment of schizophrenia and bipolar I disorder.